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Lung cancer is an aggressive disease with a high rate 
of mortality (1). Non-small cell lung cancer (NSCLC) 
constitutes approximately 85% of all histology types (2). 
In the 1990’s, chemotherapy was the standard of care 
for the treatment of metastatic NSCLC (3). Since 2005, 
targeted therapies have emerged as a new cornerstone 
in the treatment of NSCLC. These include epidermal 
growth factor receptor tyrosine kinase inhibitors (EGFR-
TKI) such as gefitinib, erlotinib, afatinib, osimertinib, and 
dacomitinib (4) as well as the anaplastic lymphoma kinase 
(ALK) inhibitors crizotinib, alectinib, ceritinib, brigatinib 
and lorlatinib (5,6). Improving our understanding of 
tumor biology has therefore become a fundamental issue 
among oncologists to optimize these novel treatment 
strategies (7). In 2018, James P. Allison and Tasuku 
Honjo (8) won the Nobel prize for their research on the 
mechanisms of the tumor immune escape, which led to 
the first immunotherapy drugs to be utilized in clinical 
practice: nivolumab and ipilimumab (3,9). The Karolinska 
Institute Nobel Prize Committee declared that Allison 
and Honjo’s findings constituted the fourth cornerstone 
of cancer treatment, alongside surgery, radiotherapy and 
chemotherapy (1,9).
Interestingly, ipilimumab, an anti-CTLA-4 monoclonal 
antibody, was the first drug targeting an immune checkpoint 
on T cells that achieved important responses in patients 
with advanced melanoma. It was therefore approved by 
the Food and Drug Administration (FDA) in 2011 for 
the treatment of metastatic melanoma (10). In 2018, 
Hellmann et al. (11) described the role of ipilimumab plus 
nivolumab for the treatment of lung cancer with a high 
tumor mutation burden (11). First-line nivolumab plus 
ipilimumab achieved significantly longer progression-free 
survival (PFS) than standard chemotherapy in advanced 
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NSCLC patients harboring a high tumor mutation burden, 
irrespective of PD-L1 expression (11). Additional drugs 
such as pembrolizumab (12,13), atezolizumab (14,15) and 
durvalumab (3) were subsequently approved alone or in 
combination with chemo/targeted therapy for the treatment 
of locally-advanced and advanced NSCLC. 
Recently, improved understanding of the molecular 
biology of  NSCLC has produced promising new 
biomarkers (16). Among of that, the understanding of a 
potential biomarker which could improve the inhibition 
of the immune check points raised as a new challenge in 
the clinical practice. Apart of PD-L1 expression, other 
molecules have been study with potential role in this field. 
One interesting example is TIM-3. It is a type I trans-
membrane protein that it is related to a novel cell surface 
molecules that would identify IFN-γ-producing Th1 
and Tc1 cells (17). One of TIM3 main role is encode the 
proteins TIM-1, TIM-3 and TIM-4 (18). It is related to 
both autoimmune and allergic diseases (17,18) and it is 
expressed on IFN-γ-producing T cells and FoxP3+ Treg 
cells, including macrophages and dendritic cells, where it 
has been shown to suppress their responses upon interaction 
with their ligand (17). More recently, TIM-3 emerged as a 
potential role in immune check points inhibitors, since It 
has been shown that it could enhances anti-tumor immunity 
and suppresses tumor growth in several preclinical tumor 
models (17). Several anti-TIM-3 targeted drugs are 
currently in clinical trials and they are considered promising 
for enhancing anti-PD-1/PDL-1 treatment when used in 
combination framework (17,18). 
In 2019, Jia et al. published a study in this prestigious 
scientific journal (18) that sought to elucidate the association 
of TIM-3 expression patterns and NSCLC immunotherapy, 
and how these correlated with overall survival (OS) (18). 
The authors assessed 139 surgically resected NSCLC 
specimens from a Polish University Oncology Center (18). 
The histological slides were independently reviewed by two 
senior pathologists (18). TILs were confirmed as TIM-3 
positive only when staining was greater than 10% (18). 
The fraction of TILs was divided into three levels: <30% 
(low), 30–60% (medium) and >60% (high). In tumor cells, 
the cutoff was set lower (>5%) due to the rare presence of 
TIM-3. The number of lymphocytes within each histology 
spot was also determined. Out of all samples tested, 9 
(6.5%) had positive TIM-3 expression on tumor cells (>5% 
staining) and 11 (7.9%) had TIM-3 positive TILs (>10% 
staining) (18). Interestingly, TIM-3 expression on TILs was 
also positively correlated with the expression of PD-L1 on 
tumor cells as well as the expression of TIM-3 on tumor 
cells and the percentage of TILs (18). Despite of that, the 
expression of TIM-3 on tumor cells only correlated with 
the expression of PD-L1 (18). 
The expression level of TIM-3 on tumor cells failed to 
predict relapsed free survival (RFS) or OS, although the 
TIM-3 positive patients demonstrated a non-significant 
reduction in survival time (18). in stage I–II patients, the 
findings did show that TIM-3 on TILs had a significant 
prognostic value. The Cox regression analysis showed 
no association of TIM-3 expression with TILs or TCs. 
Cancer stage was the only identified variable that was 
related to both RFS and OS. In addition, TIL expression 
of TIM-3 showed significant prognostic value for OS (18). 
This study suggested that TIM-3 plays a key role in the 
dysfunction of T cell immunity and could be related to 
tumor aggressiveness. The findings of this study suggest 
that further investigation of the upstream signal pathways 
that induce the co-expression of TIM-3 and PD-l/L1 are 
warranted (18). 
Currently, the synergistic effects in restoring anti-
tumor immunity in preclinical animal models could give a 
biological rational for the combination therapies based on 
blockade of TIM-3 and other inhibitory molecules, such as 
PD-1 (17). In some pre-clinical and clinical setting, multiple 
chronic viral infections, including HIV, HCV, HBV, 
Friend virus, and LCMV suggested a connection between 
elevated TIM-3 expression and exhausted CD8+ T cells. 
There are some evidence that TIM-3 acts as a checkpoint 
inhibitor for anti-tumor immunity, since its showed an 
association with T cell exhaustion in malignant tumor 
environment (17). The inhibition of TIM-3 by monoclonal 
anti-bodies (mAbs) is being assessed in different strategies 
of drugs combinations, which might include immuno-
chemotherapy and/or different immune-checkpoint 
inhibitors associations (17). Imuno-chemotherapy is one of 
the most promising approaches since the hypothesis that 
cytotoxic chemotherapy may have synergic effects with 
the tumor immunogenicity (16). Paz-Ares and colleagues 
published in 2018 the keynote 407 clinical trial that assessed 
559 previous untreated metastatic squamous NSCLC for 
the randomization of pembrolizumab plus carboplatin 
and either nanoparticle albumin-bound [nab]-paclitaxel 
or paclitaxel for four cycles followed by pembrolizumab 
maintenance. After 7.8 months follow up, the median OS as 
15.9 months to pembrolizumab-chemotherapy group versus 
11.3 months to placebo-chemotherapy combination group. 
Personally, our clinical experience is very positive with this 
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pembrolizumab-carboplatin-nab-paclitaxel regimen with 
also complete response patients and manageable toxicity 
profile. Either in 2018, Leena Gandhi was the first author 
of an interesting clinical trial named KEYNOTE 189 which 
assessed 616 metastatic non-squamous NSCLC without 
harboring sensitizing EGFR mutation or ALK fusions 
eligible for the first line systemic treatment (16). Patients 
were randomized to receive pembrolizumab versus placebo 
combined with pemetrexed-platinum regimen for four 
cycles, followed by pembrolizumab versus placebo plus 
pemetrexed maintenance. After 10.5 months follow up, 
there was a significant improvement in OS of 51% (HR 
0.49, P<0.001) for the pembrolizumab combination group. 
Despite the reported grade 3 or higher adverse events of 
67.7% in combination group versus 65.8% in placebo 
group, our patients experienced a very good tolerable 
profile with KEYNOTE 189 protocol since we have a 
multi-disciplinary specializing supportive oncology doctors’ 
team to see patients weekly in outpatient clinics, such as 
dermatologist, palliative specializing doctor, geriatrics, 
endocrinologist and cardiologist. However, the search for 
putative predictive and prognostic biomarkers is still need 
to personalize treatment for the right patient in order to 
obtain improved clinical outcomes. 
In 2018, Kato et al. published a study that assessed 
nivolumab in advanced esophageal-gastric cancer setting (19) 
which evaluated biomarkers throughout peripheral blood 
collected from 20 patients at a single institution (19). 
There was no significant differences in general examinations 
or tumor markers at baseline (19). T-cell subsets were 
analyzed by flow cytometry using stored peripheral blood 
mononuclear cells (PBMCs) (19). Authors assessed the 
expression of the immune checkpoints PD-1, TIM-3, OX40, 
4-1BB, LAG3, and ICOS, and the activation markers Ki-67 
and CD103 on CD4 and CD8 T cells and clinicopathological 
factors. After the first cycle, levels of TIM-3 were 
significantly higher in CD4 and CD8 T cells responding 
patients than non-responding patients (19). In this study, 
changes in TIM-3+CD4 levels had a significant impact 
on OS rates (19). Therefore, TIM-3 expression could be 
considered as a potential predictive and prognostic biomarker 
in this patient population. In the framework of advanced 
NSCLC, systemic treatments have undergone rapid change. 
The combination of immune-chemotherapies and targeted 
therapies have attained an important role in clinical practice. 
The use of broad Next Generation Sequence biomarker 
panels presents a promising strategy for personalizing 
medicine. TIM-3 appears to be a potential new biomarker 
that will further enable the individual tailoring of immune-
therapy protocols and thus improve patient outcomes (17) as 
well as increasing cost-effectiveness in the advanced NSCLC 
setting (15,17). However, further large phase I-III clinical 
trials are warranted to validate this hypothesis. 
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